Illumina Inc
$ 128.03
0.06%
04 Dec - close price
- Market Cap 19,678,210,000 USD
- Current Price $ 128.03
- High / Low $ 128.28 / 124.27
- Stock P/E 28.64
- Book Value 15.56
- EPS 4.47
- Next Earning Report 2026-02-05
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA 0.09 %
- ROE 0.31 %
- 52 Week High 153.06
- 52 Week Low 68.70
About
Illumina, Inc. is a leading global biotechnology company based in San Diego, California, specializing in genomic analysis technologies since its founding in 1998. Renowned for its innovative sequencing, genotyping, and gene expression solutions, Illumina serves a variety of markets, including research, clinical diagnostics, and agricultural genomics, thereby significantly contributing to the advancement of personalized medicine. The company is committed to transforming human health through ongoing innovation and has established a prominent position in the genomics landscape by enabling breakthroughs in genetic research and diagnostics.
Analyst Target Price
$121.39
Quarterly Earnings
| Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | Mar 2023 | Dec 2022 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2025-11-03 | 2025-07-31 | 2025-05-08 | 2025-02-06 | 2024-11-04 | 2024-08-06 | 2024-05-02 | 2024-02-08 | 2023-11-09 | 2023-08-09 | 2023-04-25 | 2023-02-07 |
| Reported EPS | 1.34 | 1.19 | 0.97 | 0.86 | 1.14 | 0.36 | 0.09 | 0.14 | 0.33 | 0.32 | 0.08 | 0.14 |
| Estimated EPS | 1.17 | 1.01 | 0.94 | 0.92 | 0.88 | 0.9 | 0.04 | 0.02 | 0.12 | 0.02 | 0.03 | 0.1 |
| Surprise | 0.17 | 0.18 | 0.03 | -0.06 | 0.26 | -0.54 | 0.05 | 0.12 | 0.21 | 0.3 | 0.05 | 0.04 |
| Surprise Percentage | 14.5299% | 17.8218% | 3.1915% | -6.5217% | 29.5455% | -60% | 125% | 600% | 175% | 1500% | 166.6667% | 40% |
Next Quarterly Earnings
| Dec 2025 | |
|---|---|
| Reported Date | 2026-02-05 |
| Fiscal Date Ending | 2025-12-31 |
| Estimated EPS | 1.2 |
| Currency | USD |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: ILMN
2025-11-02 10:50:07
This article explains how Artificial Intelligence (AI) is transforming genomics by providing advanced tools to analyze complex genetic and multiomic data. It details AI's role in enhancing accuracy, reducing analysis time, and facilitating comprehensive data interpretation across the genomic workflow. The content highlights Illumina's contributions to making AI accessible in genomics through partnerships, machine learning for variant calling, and explainable AI for trusted insights.
2025-10-16 20:33:23
Illumina has launched its novel 5-base solution, enabling simultaneous detection of genomic variants and DNA methylation from a single sample. This advancement, powered by proprietary 5-base chemistry and DRAGEN algorithms, provides high-resolution multiomic insights in a cost-effective workflow. The solution is already demonstrating its utility in areas like rare disease research, as highlighted by an early access customer at ASHG.
2025-10-16 14:22:04
Illumina has launched its novel 5-base solution, a significant advancement in multiomic analysis that enables the simultaneous detection of genomic variants and DNA methylation from a single sample. This solution, powered by proprietary 5-base chemistry and DRAGEN algorithms, offers high-resolution insights into both the methylome and genome, reducing complexity and cost for researchers. The technology has already shown promise in accelerating the resolution of rare disease cases and is compatible with Illumina NovaSeq and NextSeq 2000 Systems.
2025-10-16 06:19:06
Illumina has launched a novel 5-base solution that enables simultaneous detection of genomic variants and DNA methylation from a single sample, offering a cost-effective and streamlined workflow for multiomic analysis. This technology aims to provide high-resolution insights into the methylome and genome, assisting researchers in understanding disease mechanisms, discovering biomarkers, and advancing precision medicine. Early access customers, like the London Health Sciences Center Research Institute, have already demonstrated its potential in accelerating the resolution of rare disease cases.
2025-10-15 21:09:46
Genedx LLC partnered with Illumina Inc. to evaluate whether Illumina's constellation map read technology could identify hard-to-detect genetic variants associated with rare diseases. A study presented at the American Society for Human Genetics (ASHG) Annual Meeting on Oct. 15 found that Constellation technology performed as well as or better than other sequencing methods in detecting these variants across various sample types.
2025-10-15 13:44:42
Illumina Inc.'s stock experienced a 4.2% slide, leading to underperformance compared to its peers. The article also mentions Unity Software's financial results for Q4, reporting a 35% revenue increase year-over-year to $609 million, beating consensus estimates, despite a quarterly loss of 66 cents per share.
